Experimental Chlamydia Vaccine Returns Promising Results In Early-Stage Trial

MedPage Today (4/16, Haelle) reports, “An investigational vaccine against chlamydia (CTH522) induced neutralizing antibodies in all participants who received it, and with no major safety concerns, results of a phase I trial showed.” According to a study published in The Lancet Infectious Diseases, “a 100% fourfold seroconversion rate occurred in all groups receiving CTH522, a recombinant vaccine containing the major outer membrane of Chlamydia trachomatis, with no seroconversion in placebo recipients, reported” researchers.